Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | ICON8: Outcome in progression-free survival for weekly-dose paclitaxel in first-line ovarian cancer

Jonathan Ledermann, BSc, MD, FRCP, from the University College London, London, UK, provides an overview of ICON8 (NCT01654146), a UK led international trial, through the gynecological cancer intergroup. The study evaluates the weekly dose of paclitaxel in the first-line treatment of ovarian cancer. This study was implemented in different populations after results from the Japanese-led study in 2009 found a weekly dose of paclitaxel to show significant improvements in progression-free survival and overall survival. Results from the UK led ICON8, European-led MITO-7 (NCT00660842) trials, both displayed contradicting results for weekly doses of paclitaxel compared to the Japanese-led trial. Prof. Ledermann, mentions the GOG-0263 trial (NCT01101451) also comparing a weekly dose of paclitaxel against the current standard, three-week dose. In this trial, 85 percent of patients were administered bevacizumab. Again, results do not match the outcome of the Japanese-led trial. Once the data in different settings are corroborated, the standard of care can continue to evolve. Recorded at the ESMO 2017 Congress in Madrid, Spain.